Alendronate prevents angiotensin II-induced collagen I production through geranylgeranylation-dependent RhoA/Rho kinase activation in cardiac fibroblasts  by Ye, Yang et al.
ble at ScienceDirect
Journal of Pharmacological Sciences 129 (2015) 205e209Contents lists availaHOSTED BY
Journal of Pharmacological Sciences
journal homepage: www.elsevier .com/locate/ jphsFull paperAlendronate prevents angiotensin II-induced collagen I production
through geranylgeranylation-dependent RhoA/Rho kinase activation
in cardiac ﬁbroblasts
Yang Ye, Xue Lv, Mei-hui Wang, Jun Zhu, Shi-quan Chen, Chen-yang Jiang, Guo-sheng Fu*
Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, PR Chinaa r t i c l e i n f o
Article history:
Received 28 January 2015
Received in revised form
23 September 2015
Accepted 16 October 2015
Available online 2 November 2015
Keywords:
Alendronate
Collagen I
Geranylgeranylation
RhoA
Rho kinaseAbbreviations: ALN, alendronate; Ang II, angiote
analysis of variance; CF, cardiac ﬁbroblast; DMAPP, d
DMEM, Dulbecco's modiﬁed Eagle's medium; ECM,
enzyme immunoassay; FBS, fetal bovine serum; FOH
ophosphate; FPPS, farnesylpyrophosphate synthase; G
geranylgeranyl pyrophosphate; GGPPS, geranylgeran
GPP, geranyl pyrophosphate; GGTase I, geranylger
qRT-PCR, quantitative real-time polymerase chain rea
standard error; SFM, serum-free medium; TGF-b1, tra
TNF-a, tumor necrosis factor-a.
* Corresponding author. Department of Cardiology
College of Medicine, Zhejiang University, 3 East Qingc
Zhejiang Province, PR China. Tel./fax: þ86 0571 8600
E-mail addresses: yeyang1222@163.com (Y. Ye), lv
Peer review under responsibility of Japanese Pha
http://dx.doi.org/10.1016/j.jphs.2015.10.006
1347-8613/© 2015 The Authors. Production and hostin
license (http://creativecommons.org/licenses/by-nc-na b s t r a c t
Collagen I is the main component of extracellular matrix in cardiac ﬁbrosis. Our previous studies have
reported inhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced cardiac ﬁbrosis,
while the exact molecular mechanism was still unclear. This paper was designed to investigate the effect
of alendronate, a farnesylpyrophosphate synthase inhibitor, on regulating angiotensin II-induced
collagen I expression in cultured cardiac ﬁbroblasts and to explore the underlying mechanism. By
measuring the mRNA and protein levels of collagen I, we found that alendronate prevented angiotensin
II-induced collagen I production in a dose-dependent manner. The inhibitory effect on collagen I
expression was reversed by geranylgeraniol, and mimicked by inhibitors of RhoA/Rho kinase pathway
including C3 exoenzyme and GGTI-286. Thus we suggested geranylgeranylation-dependent RhoA/Rho
kinase activation was involved in alendronate-mediated anti-collagen I synthetic effect. Furthermore, we
accessed the activation status of RhoA in alendronate-, geranylgeraniol- and GGTI-286-treated cardiac
ﬁbroblasts and gave an indirect evidence for RhoA activation via geranylgeranylation. Then we came to
the conclusion that in cardiac ﬁbroblasts, alendronate could protect against angiotensin II-induced
collagen I synthesis through inhibition of geranylgeranylation and inactivation of RhoA/Rho kinase
signaling. Targeting geranylgeranylation and RhoA/Rho kinase signaling will hopefully serve as thera-
peutic strategies to reduce ﬁbrosis in heart remodeling.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
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d/4.0/).collagens, proteoglycans, glycoproteins, and proteases (1). Collagen
I comprises approximately 85% of the ECM proteins and contributes
to myocardial stiffness (2). Cardiac ﬁbroblasts (CFs), which account
for 60e70% of the cells in the heart, function as a key source of ECM
by responding to a variety of pro-ﬁbrotic stimuli [angiotensin II
(Ang II), transforming growth factor-b1 (TGF-b1), tumor necrosis
factor-a (TNF-a) etc.] (1). Thus, targeting collagen I in the CFs would
lead to a potential anti-ﬁbrotic therapy.
Alendronate (ALN) is a nitrogen-containing bisphosphonate
inhibitor of farnesylpyrophosphate synthase (FPPS). It has been
used extensively to treat bone diseases by blocking osteoclast-
mediated bone resorption (3). More recently, clinical and preclini-
cal studies supported a novel anti-neoplastic effect of ALN on
inhibiting proliferation and promoting apoptosis of various types of
cancer cells (4e6). The pleiotropic effects mediated by ALN are
attributed to down-regulation of isoprenoid intermediates [farne-
sylpyrophosphate (FPP), geranylgeranyl pyrophosphate (GGPP)
etc.] in the mevalonate pathway and the post-translationalnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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become increasingly clear that small GTPases act as important
signaling molecules in spatiotemporal regulation of a wide range of
cellular processes, including proliferation, differentiation, meta-
bolism, and survival (9). Our previous study has conﬁrmed the ef-
fects of RhoA/Rho kinase (ROCK) pathway in Ang II-induced cardiac
hypertrophic responses, which were prevented by ALN via reduced
RhoA geranylgeranylation (10). Meanwhile, Yang, J et al. (11)
recently reported cardiac-speciﬁc overexpression of FPPS, accom-
panied by increased GGPP levels and RhoA activation, could induce
cardiac hypertrophy and dysfunction in mice. Furthermore, using a
combination of pharmacologic (zolendronate) and gene silencing
approaches, we have revealed the anti-ﬁbrotic effect of FPPS inhi-
bition in Ang II-stimulated CFs, as indicated by decreased expres-
sion of collagen I, collagen III, and TGF-b1 (12). However, the
involvement of geranylgeranylation and RhoA/ROCK activationwas
still unclear and should be further explored in this context.
The present study was designed to investigate the effect of ALN
on Ang II-induced collagen I production in cultured rat CFs and to
explore the potential mechanism. A major concern in this study
was to identify whether alternative RhoA/ROCK signaling, via a
geranylgeranylation-dependent manner, was involved in ALN-
mediated anti-ﬁbrosis reaction. We utilized multiple pharmaco-
logic compounds including farnesol (FOH), geranylgeraniol
(GGOH), in addition with the inhibitors of Rho(A,B,C) (C3 exoen-
zyme), ROCK (Y27632) and geranylgeranyl transferase I (GGTase I)
(GGTI-286), to test the effects of geranylgeranylation-dependent
RhoA/ROCK pathway on Ang II-induced collagen I production. In
addition, the possible relationship between geranylgeranylation
and RhoA activation will be discussed.2. Materials and methods
2.1. Reagents
ALN, Ang II, GGOH, and FOH were purchased from Sigma (Sig-
maeAldrich Co., USA). GGTI-286 was from Calbiochem (San Diego,
CA, USA). Y27632 and C3 exoenzyme were obtained from Alexis
(San Diego, USA). All other reagents used in the experiments were
of analytical grade. FOH and GGOH are precursors of FPP and GGPP,
respectively (13).2.2. Animals
Male, 1- to 2-day-old Wistar rats were obtained from the
Experimental Animal Center, Chinese Academy of Sciences
(Shanghai, China). The investigation conformed to the Guide for the
Care and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication, 8th edition, 2011), and was
approved by the Institutional Animal Care and Use Committee of
Zhejiang University.2.3. Cell culture
Neonatal CFs were isolated from the ventricles of 1- to 2-day-old
Wistar pups with enzymatic digestion as described previously (12)
and cultured in Dulbecco's modiﬁed Eagle's medium (DMEM) with
10% (v/v) fetal bovine serum (FBS) (HyClone, Thermo Scientiﬁc,
Logan, UT, USA) in an environment containing 5% CO2 until
reaching 80e90% conﬂuence. Cells in passages 2e4 were used for
our experiments. For Ang II stimulation, the CFs were cultured in
serum-free medium (SFM) for 24 h and then treated with 0.1 mM
Ang II for 48 h.2.4. Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA extraction and qRT-PCR were performed as described
(14,15). Total RNA was isolated from cells with Trizol reagent
(Invitrogen, Carlsbad, CA, USA). Then qRT-PCRwas performed on an
ABI PRISM 7000 sequence detection system (Applied Biosystems,
Foster City, CA, USA) with SYBR Green PCR master mix (Applied
Biosystems, Foster City, CA, USA) in a total volume of 25 mP a-
tubulin was used as the endogenous control for mRNA expression.
The primers that we designed were as follows: Collagen I forward,
50-GAGCCTAACCATCTGGCATCT-30, reverse, 50-AGAACGAGG-
TAGTCTTTCAGCAAC-30; a-tubulin forward, 50-GACAGGATGCAGA
AGGAGATTACT-30, reverse, 50-TGATCCACATCTGCTGG AAGGT-30.
Each runwas completed with melting curve analysis to conﬁrm the
speciﬁcity of ampliﬁcation.
2.5. Enzyme immunoassay (ELISA)
Collagen I synthesis in medium was calculated by quantitative
sandwich enzyme immunoassay (ELISA) with a commercial kit
(BosterBiological Technology, China) according to the manufac-
turer's instruction.
2.6. RhoA activation assay
Pull-down assay to measure RhoA activation was performed
using a RhoA activation assay kit, according to the manufacturer's
protocol (Cytoskeleton, Denver, CO, USA). Sub-conﬂuent CFs were
incubated in SFM for 24 h before addition of corresponding agents
for a further 48 h. Cells were then stimulated with 0.1 mMAng II for
15 min at 37 C before addition of lysis buffer (12). A protein assay
was performed prior to the pull-down assay to equalize total pro-
tein concentration in each treatment group. The expression of both
active RhoA and total RhoA was analyzed by Western blot using a
RhoA speciﬁc antibody (Cytoskeleton).
2.7. Statistical analysis
Statistical analysis was conducted with SPSS version 20.0 soft-
ware, using one-way analysis of variance (ANOVA) for multiple
group comparisons or Student's t-test for two-group comparisons.
All data are expressed as the mean ± standard error (16). P < 0.05
was considered statically signiﬁcant.
3. Results
3.1. ALN prevents Ang II-induced collagen I synthesis by inhibition
of FFPS
The CFs were pre-treated without or with ALN (1, 3, or 10 mM) for
30 min and then co-incubated with Ang II (0.1 mM) for 48 h before
analysis. Both collagen I mRNA expression (P < 0.01 vs. control) and
protein production in medium (P < 0.05 vs. control) were signiﬁ-
cantly increased after Ang II stimulation. Moreover, treatment with
ALN could reduce the Ang II-induced collagen I synthesis in a dose-
dependent manner, with signiﬁcant difference (P < 0.05 vs. Ang II
group) at concentrations of 3 and 10 mM (Fig. 1). ALN alone did not
alter collagen I expression (data not shown).
3.2. Reversal of ALN-mediated anti-collagen I effect by GGOH but
not FOH
As ALN inhibits FPPS and blocks isoprenoid biosynthesis in the
mevalonate pathway, we next investigated whether ALN-mediated
anti-collagen I synthetic effect is associated with the downstream
Fig. 1. Effect of ALN on Ang II-mediated collagen I expression in CFs. The CFs were pre-treated without or with ALN (1, 3, or 10 mM) for 30 min and then co-incubated with Ang II
(0.1 mM) for 48 h. (A) qRT-PCR analysis of collagen I gene expression. (B) ELISA analysis of collagen I protein levels in medium. Relative expression levels of collagen I mRNA were
normalized to a-tubulin and expressed as mean ± SD, n ¼ 4. Con: control. #P < 0.05 and ##P < 0.01 vs. control group, *P < 0.05 and **P < 0.01 vs. Ang II group.
Fig. 2. Inﬂuence of GGOH on ALN-mediated anti-ﬁbrotic effect. The CFs were co-incubated with ALN (10 mM), and FOH (10 mM) or GGOH (10 mM) for 30 min followed by stimulation
with Ang II (0.1 mM) for 48 h. (A) qRT-PCR analysis of collagen I gene expression. (B) ELISA analysis of collagen I protein levels in medium. Relative expression levels of collagen I
mRNA were normalized to a-tubulin and expressed as mean ± SD, n ¼ 4. Con: control. ##P < 0.01 vs. control group, *P < 0.05 and **P < 0.01 vs. Ang II group, ※P < 0.05 vs. Ang
II þ ALN group.
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the CFs were co-incubated with 10 mM ALN, and 10 mM FOH or
10 mM GGOH, which are precursors of FPP and GGPP (13). As a
result, GGOH partially reversed the inhibitory effects of ALN on
collagen I mRNA expression (1.65 ± 0.42 vs. 0.85 ± 0.21, P < 0.05 vs.
Ang II þ ALN group) and protein production (91.33 ± 13.01 vs.
66.79 ± 2.80 ng/ml, P < 0.05 vs. Ang II þ ALN group) (Fig. 2).
Nevertheless, FOH had no inﬂuence on the ALN-mediated anti-
collagen I synthetic effect. Thus it is GGPP rather than FPP that are
implicated in ALN-induced downstream cellular processes.3.3. Effects of RhoA/ROCK inhibitors on Ang II-induced collagen I
synthesis
GGPP are essential for the post-translational modiﬁcation of Rho
family proteins through a process known as geranylgeranylation. In
the mechanism of cardiac ﬁbrosis, RhoA is one of the most studied
members. Thus we sought to investigate the role of RhoA and its
downstream effector kinase, ROCK in the Ang II-mediated collagen I
production. We found that GGTI-286 (10 mM), a speciﬁc inhibitor of
geranylgeranyl transferase-I (17), which down-regulates ger-
anylgeranylation of RhoA, mimicked the inhibitory effect of ALN on
collagen I mRNA expression and protein content in medium (Fig. 3).
Similarly, C3 exoenzyme (30 ng/ml), a speciﬁc inhibitor of RhoA
(18,19) and Y27632 (10 mM), a selective ROCK inhibitor (20,21) also
had signiﬁcant inhibitory potency on Ang II-stimulated collagen I
synthesis (P < 0.01 vs. Ang II group) (Fig. 3).3.4. Effect of ALN on RhoA activation
Given that RhoA functions between an active GTP-bound form
and an inactive GDP-bound form, RhoA activation is of great
importance for binding with different effector molecules and
initiating downstream cellular responses. The data presented thus
so far suggested that inhibition of RhoA/ROCK pathway was the
most likely mechanism.We therefore investigated the effect of ALN
on RhoA activation. The active form of RhoA was elevated to
178.87 ± 14.78% of the control group after a 15-min treatment with
Ang II (0.1 mM) (P < 0.01 vs. control) (Fig. 4). ALN markedly reduced
RhoA activation to 85.36 ± 15.88% of the control group (P < 0.01 vs.
Ang II group) (Fig. 4). Furthermore, this inactivation effect was
mimicked by GGTI-286 (10 mM) and reversed to 114.64 ± 10.45% of
control by GGOH (10 mM) (Fig. 4). FOH had no inﬂuence on RhoA
activation (Fig. 4). These results suggested that inhibition of RhoA
geranylgeranylation and the resulting down-regulation of RhoA
activation were responsible for most of the ALN-mediated anti-
collagen I synthetic effect.4. Discussion
The present study revealed that ALN could protect against Ang
II-induced collagen I synthesis in CFs. The underlying mechanism
involved inhibition of geranylgeranylation in the mevalonate
pathway and the resultant down-regulation of RhoA/ROCK
signaling. To our knowledge, this study is the ﬁrst to demonstrate
Fig. 3. Effects of RhoA/ROCK inhibitors on Ang II-induced collagen I synthesis. The CFs were pre-incubated with Y27362 (10 mM), GGTI-286 (10 mM), C3 exoenzyme (30 ng/mL), or
ALN (10 mM) for 30 min and then stimulated with Ang II (0.1 mM) for 48 h. (A) qRT-PCR analysis of collagen I gene expression. (B) ELISA analysis of collagen I protein levels in
medium. Relative expression levels of collagen I mRNA are normalized to a-tubulin and expressed as mean ± SD, n ¼ 4. Con: control. ##P < 0.01 vs. control group, **P < 0.01 vs. Ang
II group.
Fig. 4. Effects of ALN, GGTI-286 and GGOH on RhoA activation. The CFs were incubated
with ALN (10 mM), GGTI-286 (10 mM), GGOH (10 mM) or FOH (10 mM) for 24 h and then
stimulated with Ang II (0.1 mM) for 15 min. (A) The protein levels of active RhoA (upper
panel) and total RhoA (middle panel) in the cell lysates were measured by Western
blot. (B) Relative protein expression levels of active and total RhoA are normalized to a-
tubulin and expressed as mean ± SD, n ¼ 4. Con: control. ##P < 0.01 vs. control group,
**P < 0.05 vs. Ang II group, ※P < 0.05 vs. Ang II þ ALN group.
Fig. 5. The anti-ﬁbrotic effect of ALN via geranylgeranylation-dependent RhoA/ROCK
activation in neonatal CFs. GGOH and FOH can be converted to GGPP and FPP in cells.
GGTI-286 suppresses GGTase I and down-regulates geranylgeranylation of RhoA. C3
exoenzyme acts as a speciﬁc inhibitor of RhoA. Y27632 is a selective ROCK inhibitor,
targeting the RhoA-dependent downstream signaling pathway. Abbreviations: IPP,
isopentenyl pyrophosphate; FPP, farnesylpyrophosphate; GGPP, geranylgeranyl pyro-
phosphate; GGTase I, geranylgeranyl pyrophosphate type I; ROCK, Rho-kinase.
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tion of collagen I synthesis by rat CFs.
In our vitro model of Ang II-mediated cardiac ﬁbrosis, ALN
inhibited collagen I production at both mRNA and protein expres-
sion levels in a concentration-dependent manner. As one of the key
enzymes in the mevalonate pathway, FPPS is responsible for the
isoprenoid intermediates synthesis, such as FPP and GGPP (7)
(Fig. 5). Both FPP and GGPP are essential for the post-
translational modiﬁcation of small GTPases through the process
of “farnesylation” and “geranylgeranylation”. As previously re-
ported, GGOH and FOH can be converted by cells to activated forms
and served as the geranylgeranyl and farnesol donors for post-
translational modiﬁcation (13,22). In our study, the inhibitoryeffects of ALN on collagen I synthesis were reversed by addition of
GGOH, rather than FOH. This suggested geranylgeranylated pro-
teins are potential targets. The known geranylgeranylated GTPases
include the Rho family proteins, such as RhoA/B/C, Rac-1, and Cdc42
(7). Geranylgeranylation of the Rho proteins is catalyzed by the
cytosolic geranylgeranyl pyrophosphate type I (GGTase I) (23). Our
results suggested that blocking GGTase I activity with GGTI-286 led
to decreased collagen I expression. Therefore, reduced GGPP syn-
thesis and the down-regulation of geranylgeranylation could help
to explain ALN-mediated anti-collagen I synthetic effect.
Among Rho proteins, the signiﬁcance of RhoA and its major
downstream effector ROCK in cardiac ﬁbrosis has been highlighted
by recent studies (24e27). These results conﬁrmed that in vivo,
Y. Ye et al. / Journal of Pharmacological Sciences 129 (2015) 205e209 209RhoA/ROCK contributes to ﬁbrotic phenotype in response to
various pathological stimuli including Ang II. Our data, in agree
with the previous ﬁndings, indicated both inhibitors of RhoA (C3
exoenzyme) and ROCK (Y27632) could attenuate Ang II-induced
collagen I expression. In addition, the RhoA activation assay
revealed a higher level of the active GTP-bound form of RhoA in
response to Ang II. Thus we targeted RhoA/ROCK as the down-
stream signaling pathway that lead to collagen I synthesis in Ang II-
stimulated CFs, thereby linking activation of RhoA to the ALN-
mediated cellular process.
Geranylgeranylation is considered essential for activation of the
Rho proteins (28). There has been considerable support for the
notion that blocking geranylgeranylation inactivates Rho proteins
(29e31). However, this viewwas challengedmore recently by Khan
OM et al. (23), as indicated that blocking geranylgeranylation led to
accumulation of GTP-bound active RhoA, Rac1, and Cdc42 in mac-
rophages. They defended geranylgeranylation serves to inhibit,
rather than activate, Rho proteins and suggested a need to reeval-
uate the importance of Rho protein geranylgeranylation in other
speciﬁc cellular processes. The present study, utilizing RhoA acti-
vation assay, assessed the GTP-bound activation status of RhoA in
ALN- and GGTI-treated CFs. From our results, both ALN and GGTI-
286 decreased the levels of active RhoA. Meanwhile co-treatment
with GGOH reversed the inactivation effect of ALN. Thus we still
provided an indirect evidence of RhoA activation via geranylger-
anylation, at least in CFs, thereby shed new light on mechanisms
underlying anti-ﬁbrotic effects of ALN.
In conclusion, our novel ﬁndings suggest that
geranylgeranylation-dependent RhoA/ROCK activation is impli-
cated in Ang II-mediated collagen I production. Moreover, ALN is a
powerful inhibitor of collagen I synthesis via antagonism of ger-
anylgeranylation. These results will further our understanding of
CFs in response to the renineangiotensin system. In addition, we
provide new evidence indicating that targeting geranylgeranylation
and RhoA/ROCK signaling may be of potential therapeutic value in
cardiac ﬁbrosis.
A limitation of our study is that we measured collagen I pro-
duction after 48 h of Ang II treatment. However, additional time-
points of Ang II treatment should be detected to better assess-
ment of the dynamic changes.
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